SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : The Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: SirRealist who wrote (48183)5/23/2001 5:32:33 PM
From: SirRealist  Read Replies (1) of 49816
 
09:55 ET Genome Thera (GENE) 10.41 +0.91 (+9.5%): Ladenburg Thalmann morning drawing buyers to the stock; GENE was one of four genomics stocks initiated this morning by the firm with Strong Buy ratings; causing stock to stand out from the rest of group is firm's extremely aggressive price target... Ladenburg Thalmann sees stock reaching $84 over the next 12 months; expects company's expertise in using pathogen genomes to lead to the discovery of several anti-infective agents; firm arrives at valuation using a multiple to R&D expenditures, which averages 54x for drug companies and 65x for large cap biotechs.

But see how they do the valuation:
www2.marketwatch.com{4BA6365C-336A-4F39-842D-FCF8BAF80F37}&symb=GENE&sid=1285

Key will be if it breaks 14 tomorrow; if so, it can easily run to 18. I suspect it will at least hit 16 on this report, and other bios may follow tomorrow.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News